Correlation Between Brogent Technologies and Golden Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Brogent Technologies and Golden Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Brogent Technologies and Golden Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Brogent Technologies and Golden Biotechnology, you can compare the effects of market volatilities on Brogent Technologies and Golden Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Brogent Technologies with a short position of Golden Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Brogent Technologies and Golden Biotechnology.

Diversification Opportunities for Brogent Technologies and Golden Biotechnology

0.54
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Brogent and Golden is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Brogent Technologies and Golden Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Golden Biotechnology and Brogent Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Brogent Technologies are associated (or correlated) with Golden Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Golden Biotechnology has no effect on the direction of Brogent Technologies i.e., Brogent Technologies and Golden Biotechnology go up and down completely randomly.

Pair Corralation between Brogent Technologies and Golden Biotechnology

Assuming the 90 days trading horizon Brogent Technologies is expected to generate 1.07 times more return on investment than Golden Biotechnology. However, Brogent Technologies is 1.07 times more volatile than Golden Biotechnology. It trades about 0.0 of its potential returns per unit of risk. Golden Biotechnology is currently generating about -0.09 per unit of risk. If you would invest  15,700  in Brogent Technologies on September 29, 2024 and sell it today you would lose (1,000.00) from holding Brogent Technologies or give up 6.37% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy99.22%
ValuesDaily Returns

Brogent Technologies  vs.  Golden Biotechnology

 Performance 
       Timeline  
Brogent Technologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Brogent Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Golden Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Golden Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Brogent Technologies and Golden Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Brogent Technologies and Golden Biotechnology

The main advantage of trading using opposite Brogent Technologies and Golden Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Brogent Technologies position performs unexpectedly, Golden Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Golden Biotechnology will offset losses from the drop in Golden Biotechnology's long position.
The idea behind Brogent Technologies and Golden Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance